---
title: "\"Performance\" TOUYUN BIOTECH turned a loss into a profit of 11.63 million yuan last year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280942623.md"
description: "TOUYUN BIOTECH announced its full-year results for the year ended December last year, with revenue from the sale of goods and services amounting to HKD 71.948 million, a year-on-year decrease of 21.7%. It turned a loss into a profit, earning HKD 11.632 million, compared to a loss of HKD 78.899 million in the same period last year; earnings per share were HKD 0.0095. No dividend was declared"
datetime: "2026-03-30T01:54:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280942623.md)
  - [en](https://longbridge.com/en/news/280942623.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280942623.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280942623.md) | [繁體中文](https://longbridge.com/zh-HK/news/280942623.md)


# "Performance" TOUYUN BIOTECH turned a loss into a profit of 11.63 million yuan last year

TOUYUN BIOTECH (01332.HK) announced its full-year results for the year ended last December, with revenue from the sale of goods and services amounting to HKD 71.948 million, a year-on-year decrease of 21.7%. It turned a loss into a profit of HKD 11.632 million, compared to a loss of HKD 78.899 million in the same period last year; earnings per share were HKD 0.0095. No dividend was declared

### Related Stocks

- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [TOUYUN BIOTECH (01332.HK)](https://longbridge.com/en/quote/01332.HK.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md)
- [UCB presents new Bimzelx data at AAD](https://longbridge.com/en/news/280813909.md)
- [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/en/news/280992698.md)
- [Novo Nordisk Wins FDA Nod for First Once‑Weekly Basal Insulin Awiqli in U.S.](https://longbridge.com/en/news/280789111.md)
- [22:54 ETHugel to enter ECM-based injectable market with aesthetic portfolio expansion](https://longbridge.com/en/news/281291767.md)